Jul 18, 2023, 19:39
Venetoclax helps to eliminate the adverse prognostic impact of splicing factor mutations in pts with newly diagnosed AML
Quoting Hagop Kantarjian on Twitter, “MD Anderson Cancer Center’s Leukemia researchers identify the use of venetoclax helps to eliminate the adverse prognostic impact of splicing factor mutations in pts with newly diagnosed AML.”
For article: Click here
Source: Hagop Kantarjian/Twitter
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Oct 9, 2024, 12:36
Oct 9, 2024, 12:05
Oct 9, 2024, 11:35
Oct 9, 2024, 11:30